International Stem Cell Corporation (OTCBB: ISCO) today announced that
Representative Brian Bilbray recently met with Company executives,
including Chairman Kenneth Aldrich, President and Chief Executive
Officer Andrey Semechkin, and Senior Vice President Kurt May, to discuss
key federal government issues relating to stem cell research. Rep.
Bilbray represents California's 50th congressional district,
which includes portions of San Diego's North County.
Following the meeting, Rep. Bilbray stated, "I have tremendous respect
for the innovative healthcare companies in my district, such as
International Stem Cell, that are at the forefront of developing
important new treatments and therapies. I'm committed to helping remove
unnecessary regulations and barriers that may inhibit the research of
new life science technologies, and I greatly appreciate the efforts of
ISCO's management team to clarify many of the issues surrounding their
work."
Said Dr. Semechkin, "We are very pleased to have the opportunity to meet
with Congressman Bilbray and explain the importance of our
parthenogenesis technology and how it differs from human embryonic stem
cell development, particularly from an ethical standpoint. We look
forward to continued discussions with Congressman Bilbray and his
colleagues regarding the Dickey-Wicker Amendment. We believe that with
increased understanding of our technology the National Institutes of
Health (NIH) will support parthenogenesis research and development."
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic
applications of human parthenogenetic stem cells (hpSCs) and the
development and commercialization of cell-based research and cosmetic
products. ISCO's core technology, parthenogenesis, results in the
creation of pluripotent human stem cells from unfertilized oocytes
(eggs). hpSCs avoid ethical issues associated with the use or
destruction of viable human embryos. ISCO scientists have created the
first parthenogenic, homozygous stem cell line that can be a source of
therapeutic cells for hundreds of millions of individuals of differing
genders, ages and racial background with minimal immune rejection after
transplantation. hpSCs offer the potential to create the first true stem
cell bank, UniStemCell™. ISCO also produces and markets specialized
cells and growth media for therapeutic research worldwide through its
subsidiary Lifeline Cell Technology, and cell-based skin care products
through its subsidiary Lifeline Skin Care. More information is available
at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click
on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, and other
opportunities for the company and its subsidiaries, along with other
statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited
to statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates,") should also be considered to be
forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products and the
management of collaborations, regulatory approvals, need and ability to
obtain future capital, application of capital resources among competing
uses, and maintenance of intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the company's business, particularly
those mentioned in the cautionary statements found in the company's
Securities and Exchange Commission filings. The company disclaims any
intent or obligation to update forward-looking statements.
International Stem Cell Corporation
Kenneth
C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn
& Associates
Don Markley
310-691-7100
dmarkley@lhai.com